분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-07 14:06:16 , Hit : 1522
 J&J Wins U.S. Approval for Hepatitis C Combo With Gilead



Bloomberg News

By Anna Edney   November 06, 2014

--------------------------------------------------------------------------------

      Johnson & Johnson (JNJ:US) won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc. (GILD:US)’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus.

The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement. The combination allows Olysio to be used without the standard therapies including interferon, an injection that sometimes has flu-like side effects.

The price of hepatitis C treatments has been criticized by insurers and lawmakers since Foster City, California-based Gilead’s Sovaldi was approved in December with an $84,000 price tag for a full course of treatment. The FDA on Oct. 10 cleared Gilead’s Harvoni, a once-daily pill that treats patients who have the most common form of the virus without using the older drugs. Harvoni has an estimated cost of $94,500 for 12 weeks.

Video: Stockton, CA, Wins Court Approval of Bankruptcy Plan

J&J hasn’t changed the $66,000 price for 12 weeks of therapy with Olysio since it was first cleared for use with older medicines in the U.S. a year ago, said Rebecca Tillet, a company spokeswoman. J&J plans to work with insurance companies and other payers to ensure it continues to provide access to patients, she said in a telephone interview.

“There are a lot of different patients needs,” she said. “We think Olysio will play a meaningful role in that mix.”

Patient Population

About 3.2 million people in the U.S. have hepatitis C, which can cause liver cirrhosis according to the Centers for Disease Control and Prevention. The most common form of the virus is genotype 1, which affects about 75 percent of patients. J&J, based in New Brunswick, New Jersey, and Swedish drugmaker Medivir AB (MVIRB) sell Olysio. The drug, in combination with ribavirin and interferon, can treat patients in 24 weeks, half the time of older medicines.

Video: Apple Wins in Court, Won’t Pay $93.7M Fine

J&J, the world’s largest health-care products company, reported Olysio revenue (JNJ:US) of almost $2 billion in the first three quarters of this year. Sovaldi has generated $8.6 billion in sales during the same time period.

Patients have been able use J&J’s Olysio and Gilead’s Sovaldi together without FDA clearance at a cost of $150,000. Doctors may prescribe drugs approved for specific diseases to treat other ailments in a practice called off-label use.

The drugs are part of a push to shorten treatment times while improving cure rates and eliminating unpleasant side effects. Older drugs include Merck & Co.’s Victrelis and Vertex Pharmaceuticals Inc. (VRTX:US)’s Incivek.

Video: Nurse Wins Freedom From New Jersey Ebola Quarantine

The FDA approved the combination treatment for a standard 12 weeks of therapy if patients don’t have cirrhosis and 24 weeks for those who do, according to the drug’s prescribing label.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editors responsible for this story: Crayton Harrison at tharrison5@bloomberg.net Andrew Pollack, James Callan







987   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1921
986   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1127
985   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1491
984   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1159
983   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1592
982   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1657
981   AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1185
980   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1065
979   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1467
978   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1663
977   간 이식 환자들의 C형 간염에 효과적인 병용 요법  이성욱 2014/11/13 1606
  J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1522
975   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1278
974   실험실에서 만든 인공위장  이성욱 2014/11/04 1220
973   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1492
972   어떻게 복잡한 생명은 진화했는가?  이성욱 2014/10/31 1601
971   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1561
970   As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  이성욱 2014/10/31 1346
969   암의 우군-엑소좀(exosome)  이성욱 2014/10/29 2787
968   이웃의 정상세포를 감염시키는 암세포  이성욱 2014/10/27 1464

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN